Nuvasive, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$95Mgeneral payments (2019-2025)
$171Kresearch payments (2019-2025)
5,136clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Reline $5.8M associated (2023-2025)
- Precept $4.3M associated (2023-2025)
- Modulus $3.3M associated (2023-2025)
- Brigade $3.3M associated (2023-2025)
- Base $3.2M associated (2023-2025)
- Versatie $3.1M associated (2023-2025)
- Pulse $2.2M associated (2023-2025)
- Xlif $1.7M associated (2023-2025)
- Coroent $1.6M associated (2023-2025)
- Vuepoint $1.5M associated (2023-2025)
- Alif $1.5M associated (2023-2025)
- Cohere $1.4M associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Regis Haid | Atlanta, GA | Neurological Surgery | $13,681,015.10 |
| Robert Isaacs | Durham, NC | Neurological Surgery | $4,677,547.31 |
| Juan Uribe | Phoenix, AZ | Neurological Surgery | $3,524,537.45 |
| Jim Youssef | Durango, CO | Orthopaedic Surgery of The Spine | $2,094,531.57 |
| Gregory Mundis | La Jolla, CA | Orthopaedic Surgery of The Spine | $1,968,847.63 |
| Christopher Brown | Durham, NC | Orthopaedic Surgery | $1,883,718.47 |
| Frank Phillips | Chicago, IL | Orthopaedic Surgery of The Spine | $1,710,317.92 |
| Behrooz Akbarnia | La Jolla, CA | Orthopaedic Surgery | $1,703,687.99 |
| Kamal Ibrahim | Oakbrook Terrace, IL | Orthopaedic Surgery | $1,692,246.78 |
| Christopher Shaffrey | Durham, NC | Neurological Surgery | $1,648,962.65 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.